The biggest barriers to stopping the transmission of HIV are both the large population of infected people not receiving treatment and the lack of pre-exposure prophylaxis for high-risk individuals, said Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health.
The biggest barriers to stopping the transmission of HIV are both the large population of infected people not receiving treatment and the lack of pre-exposure prophylaxis for high-risk individuals, said Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health.
Transcript
What are the barriers to preventing the transmission of HIV/AIDS?
I think as we learn more and do more studies on the use of pre-exposure prophylaxis, that the data’s going to be overwhelming. I mean, we’re really only two, three years into these studies and I think it does take some time. Also, the cost needs to decrease. But I think as we do more studies, show more efficacy, and get better acceptance in the countries that have been reticent to accept it, I think we’ll make some headway. So that’s number one.
The second means of prevention is treating the HIV-infected person. So, how are we doing with that? Right now, probably less than 45 percent of the world’s HIV population is under treatment and virally suppressed. So that’s good news, that those individuals are non-infectious or less infectious to their sexual partners, but that means 55 percent of the world’s population is untreated. And that is probably one of the biggest barriers.
It’s getting people to, one, be screened and be tested and to know they’re infected, two, to get them into care, and three, to get them put onto anti-retroviral drugs once in care, and then fourth and lastly, make sure they’re suppressed. If they’re virally suppressed, they’re non-infectious. There’s really been almost no transmissions of individuals who have a completely suppressed viral load of HIV. So I would say the two biggest barriers right now in prevention is not enough people on treatment that need to be on treatment and virally suppressed, and two, the high-risk individuals not getting pre-exposure prophylaxis, which can block HIV acquisition.
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Recognizing Symptoms of Myeloproliferative Neoplasms and Clinical Trial Challenges
October 24th 2024There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.
Read More
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More